Cancer diagnostics company Pacific Edge (ASX:PEB) has released its investor update for the three months ended December 2025, highlighting key strategic developments aimed at reinstating Medicare coverage for its Cxbladder tests and reporting on test volumes processed through its laboratories.
It also notes that Kaiser Permanente’s Real World Evidence study demonstrating Cxbladder Triage's clinical utility has been accepted for publication in Urology Practice, potentially strengthening Pacific Edge’s position at the CAC.
The company reported ongoing progress in Medicare appeals for Cxbladder Triage tests denied reimbursement following the Genetic Testing for Oncology LCD (L39365) that ended coverage.
The first of four hearings is scheduled for Feb. 24, immediately after the CAC meeting.
Laboratory throughput fell 13.4% in Q3 26 to 5,446 tests from 6,286 in Q2 26, with US volumes down 19.5% to 4,003 tests, while APAC volumes rose 9.7% to 1,443 tests, driven by commercial test growth.
Additional highlights include Avalon Healthcare Systems endorsing Cxbladder Triage as "meeting coverage criteria," providing further evidence to support Medicare discussions, and the appointment of Simon Flood as the company’s new Chair following Chris Gallaher's retirement.
At the time of reporting, Pacific Edge's share price was $0.17.